🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Munich
Clinical trial register · Germany

Clinical Trials in Munich, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Technical University of Munich31 Merck Sharp & Dohme LLC26 AbbVie22 Novartis Pharmaceuticals21 Ludwig-Maximilians - University of Munich21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Munich

405 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsBMS-986393·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg
2025-03-12
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Stuttgart, Munich, Herne, Halle, Jena
2025-03-11
Recruiting
Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation
NCT06825104Atrial Fibrillation
Volta Medical
Observational
278
Coburg, Munich
2025-03-06
Recruiting
Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma
NCT06600165Basal Cell Carcinoma
LMU Klinikum
Observational
1,000
Munich
2025-03-01
Recruiting
A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET
NCT06859203Biochemical Recurrence of Malignant Neoplasm of Prostate
Technical University of Munich
Observational
94
Augsburg, Munich
2025-03
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2
200
Munich
2025-02-25
Active, closed
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
NCT06811805AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
CardioRenal Systems, Inc.
Not applicable
300
Munich, Münster
2025-02-23
Active, closed
Prehabilitation in Childhood Soft Tissue or Bone Sarcomas
NCT06743958Soft Tissue Sarcoma of the Lower Extremity, Bone Tumor of the Lower Extremity, Childhood and Adolescent Cancer
Technical University of Munich
Not applicable
16
Munich
2025-02-20
Recruiting
Local and Systemic Oxygen Saturation During 'Death by Squats' Exercise
NCT06884644Oxygen Saturation, Fatigue, Anaerobic Threshold, Quadriceps Muscle
Bundeswehr University Munich
Observational
100
Munich
2025-02-08
Recruiting
Assessment of Physical Activity and Cardiovascular Outcomes in Patients With Chronic Heart Failure
NCT07460531Heart Failure
LMU Klinikum
Observational
2,000
Munich
2025-02-01
By invitation
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
170
Berlin, Frankfurt, Munich
2025-02-01
Not yet open
This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)
NCT06817915Neovascular Age-Related Macular Degeneration (nAMD)
Johannes Schiefelbein
Not applicable
100
Munich
2025-01-30
Recruiting
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma
NCT06657157Urothelial Cancer
Comprehensive Cancer Center Munich (CCCM)
Observational
80
Augsburg, Munich, Würzburg
2025-01-22
Recruiting
ioMRI in the Surgery of Brain Metastases.
NCT07197632Brain Metastases
Technical University of Munich
Not applicable
154
Munich
2025-01-17
Recruiting
Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage
NCT06749106Acute Ischemic Stroke
Ludwig-Maximilians - University of Munich
Observational
300
Munich
2025-01-16
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Tübingen, Munich, Hamburg, Hanover
2025-01-15
Recruiting
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.
NCT06836011ATTR Amyloidosis With Cardiomyopathy, ATTR-CM, ATTR Amyloidosis Wild Type, Mitral Regurgitation
Medical University of Vienna
Observational
600
Munich, Frankfurt am Main
2025-01-01
By invitation
i-Stitch for Bilateral Sacrospinous Ligament Fixation (SSLF)
NCT06805006Pelvic Organ Prolapse, Genital Prolapse
A.M.I. Agency for Medical Innovations GmbH
Observational
100
Munich
2025-01-01
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
240
Dresden, Munich, Schwerin, Würzburg
2024-12-17
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Leucovorin·Fluorouracil
AbbVie
Phase 2
185
Freiburg im Breisgau, Munich, Frankfurt am Main, Leipzig, Hamburg
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Adrucil
Janssen Research & Development, LLC
Phase 3
700
Berlin, Frankfurt am Main, Heidelberg, Mainz, Munich
2024-12-12
Recruiting
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
NCT06623890Friedreich Ataxia
DrugsOmaveloxolone·Skyclarys
Biogen
Observational
300
Tübingen, Aachen, Munich
2024-12-12
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Munich, Frankfurt am Main, Obertshausen, Cologne, Augsburg, Berlin, Freiburg im Breisgau, Hamburg
2024-12-08
Active, closed
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 3
129
Hamburg, Leipzig, Munich
2024-12-03
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
48
Dresden, Düsseldorf, Göttingen, Leipzig, Munich
2024-12-03
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Munich, Frankfurt am Main, Cologne, Berlin
2024-12-02
Recruiting
Fast Discharge After Acute Myocardial Infarction Discharge MI
NCT06744322Acute Myocardial Infarction (AMI)
Medical University Innsbruck
Not applicable
2,070
Munich
2024-12-01
Recruiting
Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity
NCT06806059Urothelial Carcinoma Bladder
Ludwig-Maximilians - University of Munich
Not applicable
146
Munich
2024-11-29
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
Munich, Bochum, Hamburg, Tübingen
2024-11-25
Recruiting
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498Alzheimers Disease, Dementia, Alzheimers Disease, Familial
DrugRemternetug
Washington University School of Medicine
Phase 2/3
280
Tübingen, Munich
2024-11-22
Recruiting
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157Alzheimers Disease, Dementia, Alzheimers Disease, Familial
DrugRemternetug
Washington University School of Medicine
Phase 2/3
280
Tübingen, Munich
2024-11-22
Recruiting
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
NCT06712628Moderate to Severe Rheumatoid Arthritis
AbbVie
Observational
678
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Marktredwitz, Munich
2024-11-07
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
DrugVHB937
Novartis Pharmaceuticals
Phase 2
251
Mannheim, Munich, Würzburg, Rostock, Berlin, Hanover, Lübeck, Münster
2024-10-17
Recruiting
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089Arthritis, Psoriatic
DrugsSonelokimab·Risankizumab
MoonLake Immunotherapeutics AG
Phase 3
600
Berlin, Dresden, Erlangen, Frankfurt, Hamburg, Herne, Munich, München
2024-10-15
Active, closed
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
960
Bad Bentheim, Berlin, Erlangen, Hamburg, Herne, Munich, München
2024-10-15
Recruiting
Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke
NCT06005233Ischemic Stroke, Cryptogenic, Transient Ischemic Attack, Atrial Fibrillation
Technical University of Munich
Not applicable
400
Munich
2024-10-15
Active, closed
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
NCT06631079Solid Tumor
NEC Bio B.V
Phase 1/2
20
Berlin, Heidelberg, Munich
2024-10-07
Active, closed
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
NCT06642506Esophagus Adenocarcinoma, Esophagus Cancer, Metabolome, Mass Spectrometry
Ludwig-Maximilians - University of Munich
Observational
20
Munich
2024-10-06
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
Homburg, Jena, Munich
2024-10-03
Active, closed
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
NCT06504446Refractory or Unexplained Chronic Cough
Nocion Therapeutics
Phase 2
455
Munich, Darmstadt, Frankfurt am Main, Marburg, Halle, Geesthacht, Lübeck, Berlin
2024-09-24
Active, closed
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
151
Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum
2024-09-18
Recruiting
European Registry of Next Generation Imaging in Advanced Prostate Cancer
NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
Fundacio Puigvert
Observational
600
Bonn, Hamburg, Munich, Planegg, Tübingen
2024-09-17
Active, closed
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751Tourette Syndrome
Noema Pharma AG
Phase 2
164
Düsseldorf, Hanover, Munich
2024-09-10
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Munich, Regensburg, Frankfurt am Main, Fulda
2024-09-04
Recruiting
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
NCT06517719Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals
Observational
500
Konstanz, Stuttgart, Munich, Regensburg, Würzburg, Cottbus, Frankfurt (Oder), Ludwigshafen
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg
2024-09-03
Recruiting
CRS Questionnaire Validation Project
NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
The European Forum for Research and Education in Allergy and Airway Diseases
Observational
1,000
Düsseldorf, Munich
2024-09-01
Recruiting
The TRICURE EU Pivotal Study
NCT06581471Tricuspid Valve Regurgitation, Heart Valve Disease, Cardiovascular Diseases
TRiCares
Not applicable
80
Mainz, Munich
2024-08-29
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
DrugsKYV-101·Fludarabine·Cyclophosphamide
Kyverna Therapeutics
Phase 2/3
66
Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, Munich
2024-08-28
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsICS/LABA·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
Augsburg, Munich, Frankfurt am Main, Koblenz, Lübeck, Berlin, Leipzig, Mainz
2024-08-26
Recruiting
Observational Study of Venus P-Valve
NCT05835349Right Ventricular Outflow Tract Dysfunction
Venus MedTech (HangZhou) Inc.
Observational
200
Munich, Berlin
2024-08-26
Recruiting
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
NCT06720532Kidney Disease, Radiation Nephropathy, Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Hannah Schaefer
Observational
100
Munich
2024-08-05
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Kirchheim unter Teck, Munich, Ludwigshafen, Berlin, Mainz
2024-08-05
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Weinheim, Munich, Freiberg, Berlin, Cologne, Dachau, Dippoldiswalde, Dresden
2024-08-01
Recruiting
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
NCT06389968Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Technical University of Munich
Not applicable
50
Munich
2024-08-01
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Munich, Regensburg, Würzburg, Frankfurt am Main, Bochum, Essen
2024-07-31
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
686
Heidelberg, Heilbronn, Schwäbisch Hall, Munich, Marburg, Düsseldorf, Essen, Worms
2024-07-24
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
Beelitz, Düsseldorf, Leipzig, Munich
2024-07-23
Recruiting
Clinical Performance of the New Plasma Filter PX2 in TPE Treatments
NCT06382675Autoimmune Diseases
Fresenius Medical Care Deutschland GmbH
Not applicable
46
Aschaffenburg, Munich, Braunschweig, Paderborn, Berlin, Ulm, Würzburg
2024-07-18
Recruiting
Evaluation of the Naturalistic User Experience of the Website "ich Bin Alles @Schule" (i Am Everything @school)
NCT06668688Depression, Depressive Disorder, Depression in Children, Depression in Adolescence
Ludwig-Maximilians - University of Munich
Observational
100
Munich
2024-07-05
Recruiting
Comparison Between Ureterorenoscopy With Lithotripsy Alone Versus Combination With Hydrogel for Kidney Stone Removal
NCT06469736Nephrolithiasis, Lithotripsy, Laser, Ureteroscopy
Technical University of Munich
Not applicable
120
Munich
2024-07-01
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Freiburg im Breisgau, Ludwigsburg, Tübingen, Erlangen, Munich, Potsdam, Georgsmarienhütte, Hanover
2024-06-24
Recruiting
Suprasorb® CNPendo Used for Negative Pressure Therapy in the Oesophagus and Rectum to Support Defect and Wound Healing
NCT05476263Esophagus Injury, Rectal Lesion
Lohmann & Rauscher
Observational
110
Berlin, Mannheim, Munich, Münster, Rheine, Tübingen
2024-06-03
Recruiting
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
NCT06474806Prostate Cancer
Curasight
Phase 2
168
Chemnitz, Düsseldorf, Hamburg, Munich
2024-06-01
By invitation
Invasive Versus Echocardiography-derived Transvalvular Gradients After TAVI Usign Balloon-expandable Transcatheter Heart Valves.
NCT06753227AORTIC VALVE DISEASES, Aortic Stenosis
Deutsches Herzzentrum Muenchen
Observational
250
Munich
2024-05-28
Active, closed
The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients
NCT07126860Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy
Ludwig-Maximilians - University of Munich
Not applicable
150
Munich
2024-05-24
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Olaparib
Merck Sharp & Dohme LLC
Phase 1/2
220
Heidelberg, Tübingen, Munich, Berlin, Hamburg
2024-05-20
Recruiting
Anti-viral Action Against Type 1 Diabetes Autoimmunity
NCT06452654Diabetes Mellitus, Type 1
DrugSodium Chloride Inj
Technical University of Munich
Phase 4
2,252
Munich, Hanover, Dresden
2024-05-08
By invitation
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD
NCT06734949Neuromuscular; Disorder, Hereditary
University of Modena and Reggio Emilia
Observational
500
Munich
2024-05-01
Recruiting
Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
NCT07137260Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, Digital Mobility Outcomes
Simon Jäger
Observational
77
Stuttgart, Munich, Nuremberg, Löwenstein
2024-04-19
Active, closed
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221Cardiomyopathy, Hypertrophic
DrugMavacamten
Bristol-Myers Squibb
Phase 3
44
Munich, Berlin
2024-04-17
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
272
Stuttgart, Munich, Dresden, Jena, Berlin, Hamburg
2024-04-10
Recruiting
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
NCT05871021Glioblastoma
University Hospital Tuebingen
Phase 2
146
Augsburg, Cologne, Frankfurt, Freiburg im Breisgau, Leipzig, Mannheim, Munich, Regensburg
2024-04-10
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Munich, München, Rosenheim, Hanover, Frankfurt, Essen, Mainz, Leipzig
2024-04-03
Recruiting
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
NCT06396312Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
Max-Planck-Institute of Psychiatry
Observational
130
Munich
2024-04-02
Recruiting
Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population
NCT06634121Mitral Regurgitation, Valvular Heart Disease, Heart Failure
LMU Klinikum
Not applicable
180
Munich
2024-04-01
By invitation
Return to Activity After Total Knee Arthroplasty
NCT07006545Total Knee Arthroplasty
University Hospital, Bonn
Observational
400
Munich, Bonn
2024-04-01
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
230
Munich, Regensburg, Dresden, Halle, Berlin
2024-03-28
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808HIV-1-infection
DrugsBictegravir·Lenacapavir·B/F/TAF
Gilead Sciences
Phase 3
577
Aachen, Berlin, Cologne, Frankfurt, Hamburg, Munich, München
2024-03-25
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
DrugsLutikizumab·Humira·Adalimumab
AbbVie
Phase 2
156
Ulm, Munich, Ludwigshafen am Rhein, Leipzig, Kiel, Hamburg
2024-03-23
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119First Progression of Glioblastoma
DrugLomustine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg
2024-03-15
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Recruiting
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
NCT06138743Myotonic Dystrophy 1
Sarepta Therapeutics, Inc.
Phase 1/2
78
Munich, Ulm
2024-03-04
Active, closed
Predicting Neuromuscular Recovery in Surgical Patients Using Machine Learning
NCT05471882Residual Paralysis, Post Anesthesia, Postoperative Complications, Neuromuscular Blockade, Quantitative Neuromuscular Monitoring
University Hospital Ulm
Observational
240,000
Ulm, Munich
2024-03-01
Recruiting
Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT06834152Localized Prostate Carcinoma, Prostate Cancer (Adenocarcinoma), Prostate Hyperplasia, Lower Urinary Track Symptoms
University of Zurich
Observational
75
Heidelberg, Munich
2024-03-01
Active, closed
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173Alzheimer Disease
Acumen Pharmaceuticals
Phase 2
542
Berlin, Cologne, Mannheim, Munich
2024-02-29
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Freiburg im Breisgau, Munich, Regensburg, Weiden in Der Oberpfalz, Langen, Hildesheim, Bergisch Gladbach, Bielefeld
2024-02-28
Recruiting
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
NCT06482684Mantle Cell Lymphoma
DrugsTecartus·Ibrutinib
Christian Schmidt, MD
Phase 2
150
Mainz, Munich
2024-02-15
Recruiting
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
NCT05704829HER2-positive Early Breast Cancer
DrugTrastuzumab deruxtecan
Women's Cancer Study Group GmbH
Phase 2
702
Baden-Baden, Freiburg im Breisgau, Tübingen, Ulm, Augsburg, Munich, Bremerhaven, Frankfurt am Main
2024-02-05
Active, closed
Study to Examine Lesions of the Skin Using Confocal Laser Microscopy
NCT06598137Benign Skin Tumor, Basal Cell Carcinoma, Melanoma, Squamous Cell Cancer
LMU Klinikum
Observational
645
Munich
2024-02-01
Active, closed
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
NCT06107426Parkinson's Disease (PD)
AbbVie
Observational
427
Wolfach, Munich, Potsdam, Osnabrück, Halle, Beelitz-Heilstätten, Bottrop
2024-01-24
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Berlin, Freiburg im Breisgau, Munich
2024-01-11
Recruiting
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
AvenCell Europe GmbH
Phase 1
37
Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen
2024-01-03
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Munich, Schwerin, Bonn, Münster, Lübeck, Jena, Berlin, Hamburg
2023-12-31
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
DrugsOdronextamab·Lenalidomide·Rituximab
Regeneron Pharmaceuticals
Phase 3
580
Mutlangen, Stuttgart, Munich, Frankfurt am Main, Essen, Mainz, Halle, Kiel
2023-12-28
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Heidenheim, Konstanz, Mannheim, Schorndorf, Stuttgart, Augsburg, Munich, Bremenhaven
2023-12-20
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Erlangen, Munich, Blankenfelde-Mahlow, Bonn, Frankfurt am Main, Bad Bentheim, Münster, Mainz
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Freiburg im Breisgau, Heidelberg, Nürtingen, Munich, Regensburg, Marburg, Göttingen, Bergisch Gladbach
2023-12-18
Recruiting
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NCT05714930Systemic Lupus Erythematosus
Heinrich-Heine University, Duesseldorf
Not applicable
606
Freiburg im Breisgau, Heidelberg, Erlangen, Munich, Frankfurt am Main, Hanover, Düsseldorf, Essen
2023-12-12
Active, closed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256Idiopathic Pulmonary Fibrosis
DrugAxatilimab
Syndax Pharmaceuticals
Phase 2
145
Konstanz, Munich, Hanover, Chemnitz, Frankfurt am Main, Gauting, Rosenheim
2023-12-11
Rows per page Showing 101–200 of 405
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/munich?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 405 of those studies with a site in Munich.

How many clinical trials are recruiting in Munich?

233 of the 405 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 12 have not yet opened recruitment, 149 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.